These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2206031)

  • 1. Extended clinical safety profile of lovastatin.
    Mantell G; Burke MT; Staggers J
    Am J Cardiol; 1990 Sep; 66(8):11B-15B. PubMed ID: 2206031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and long-term adverse effect pattern of lovastatin.
    Tobert JA
    Am J Cardiol; 1988 Nov; 62(15):28J-34J. PubMed ID: 3055921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with lovastatin.
    Tobert JA; Shear CL; Chremos AN; Mantell GE
    Am J Cardiol; 1990 Mar; 65(12):23F-26F. PubMed ID: 2180268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    Rubenfire M;
    Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up.
    Bradford RH; Shear CL; Chremos AN; Dujovne CA; Franklin FA; Grillo RB; Higgins J; Langendorfer A; Nash DT; Pool JL
    Am J Cardiol; 1994 Oct; 74(7):667-73. PubMed ID: 7942524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.
    Pierce LR; Wysowski DK; Gross TP
    JAMA; 1990 Jul; 264(1):71-5. PubMed ID: 2355431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia.
    Bradford RH; Downton M; Chremos AN; Langendörfer A; Stinnett S; Nash DT; Mantell G; Shear CL
    Ann Intern Med; 1993 Jun; 118(11):850-5. PubMed ID: 8480959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG CoA reductase inhibitors. Current clinical experience.
    Walker JF
    Drugs; 1988; 36 Suppl 3():83-6. PubMed ID: 3076126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study.
    Chucrallah A; De Girolami U; Freeman R; Federman M
    Eur Neurol; 1992; 32(5):293-6. PubMed ID: 1521554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The liver and lovastatin.
    Tolman KG
    Am J Cardiol; 2002 Jun; 89(12):1374-80. PubMed ID: 12062731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lovastatin extended release: a review of its use in the management of hypercholesterolaemia.
    Curran MP; Goa KL
    Drugs; 2003; 63(7):685-99. PubMed ID: 12656649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemfibrozil-induced myopathy.
    Magarian GJ; Lucas LM; Colley C
    Arch Intern Med; 1991 Sep; 151(9):1873-4. PubMed ID: 1888257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lovastatin and myopathy.
    Tobert JA
    Am J Med; 1994 Mar; 96(3):300-1. PubMed ID: 8154521
    [No Abstract]   [Full Text] [Related]  

  • 19. Myopathy and rhabdomyolysis with lovastatin taken with gemfibrozil.
    JAMA; 1990 Dec; 264(23):2991-2. PubMed ID: 2243420
    [No Abstract]   [Full Text] [Related]  

  • 20. Defining patient risks from expanded preventive therapies.
    Tolman KG
    Am J Cardiol; 2000 Jun; 85(12A):15E-9E. PubMed ID: 10858489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.